Work

Crizotinib in advanced ROS1-rearranged non-small cell lung cancer (NSCLC): updated results from PROFILE 1001

Year: 2016

Type: article

Source: Annals of Oncology

DOI: 10.1093/annonc/mdw383.07

Authors: A. Shaw, G.J. Riley, Y.-J. Bang, D.-W. Kim, D.R. Camidge, M. Varella-Garcia, A.J. Lafrate, G. Shapiro, M. Winter, T. Usari, S.C. Wang, K. Wilner, J.W. Clark, S.-H.I. Ou

Institutions: Massachusetts General Hospital, Memorial Sloan Kettering Cancer Center, Seoul National University Hospital, Seoul National University, University of Colorado Cancer Center, Dana-Farber Cancer Institute, Pfizer (United States), Pfizer (Italy), University of California, Irvine

Language: English

Topic: Lung Cancer Treatments and Mutations

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: bronze

Funder: Pfizer

OpenAlex ID: W2588136265

FWCI: 2.911

Cites:

Cited by: 17

Related to: 10